Measurements of insulin resistance in hypertension: Where are we now?

Journal of Human Hypertension

Volumn 21, Issue 9, 2007, Pages 693-696

  Hwu, C M ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; GLUCOSE; INSULIN; OCTREOTIDE; PROPRANOLOL; SOMATOSTATIN; TOLBUTAMIDE;

BOLUS INJECTION; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GOLD STANDARD; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; INTRAVENOUS GLUCOSE TOLERANCE TEST; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; STEADY STATE;

DIABETES MELLITUS; HUMANS; HYPERTENSION; INSULIN RESISTANCE;

EID: 34548337298     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002202     Document Type: Note

References (24)

1. Defronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14 173-194.
2. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
3. Reaven GM. Insulin resistance/compensatory hyper-insulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88: 2399-2403.
4. Mohteshamzadeh M, Wilkinson R, Thomas SHL. Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: results of a 3-year study. Am J Hypertens 2005; 18: 452-456.
5. Sarafidis PA, Bakris GL. Non-esterified fatty acids and blood pressure elevation: A mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens 2007; 21: 12-19.
6. Ustundag S, Arikan E, Sen S, Esgin H, Ciftci S. The relationship between the levels of plasma total homocysteine and insulin resistance in uncomplicated mild-to-moderate primary hypertension. J Hum Hypertens 2006; 20: 379-381.
7. Cheung BM, Leung RY, Man YB, Ong KL, Wong LY, Lau CP et al. Association of hypertension with single nucleotide polymorphisms in the quantitative trait locus for abdominal obesity-metabolic syndrome on chromosome 17. J Hum Hypertens 2006; 20: 419-425.
8. Aksnes TA, Reims HM, Guptha S, Moan A, Os I, Kjeldsen SE. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens 2006; 20: 860-866.
9. Hwu CM, Hsiao CF, Grove J, Hung YJ, Chuang LM, Chen YT et al. Surrogate estimates of insulin sensitivity in subjects with hypertension. J Hum Hypertens 2007; 21: 246-252.
10. Scheen AJ, Paquot N, Castillo MJ, Lefèbvre PJ. How to measure insulin action in vivo. Diabetes Metab Rev 1994; 10: 151-188.
11. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995; 13: 1457-1462.
12. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S et al. Insulin resistance and hypertension. The Insulin Resistance Atherosclerosis Study. Hypertension 2004; 43: 1324-1331.
13. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
14. Lin MW, Hwu CM, Huang YH, Sheu WHH, Shih KC, Chiang FT et al. Directly measured insulin resistance and the assessment of clustered cardiovascular risks in hypertension. Am J Hypertens 2006; 19 1118-1124.
15. Lansang MC, Williams GH, Carroll JS. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens 2001; 14: 51-53.
16. Chen H, Sullivan G, Yue LQ, Katz A, Quon MJ. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab 2003; 284: E804-E812.
17. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
18. Abbasi F, Reaven GM. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism 2002; 51: 235-237.
19. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A et al. Validity and reproducibility of HOMA-IR, 1/ HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type 2 diabetes. J Hum Hypertens 2007; 21: 709-716 (this issue).
20. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
21. Hanley AJG, Williams K, Gonzalez C, D'Agostino Jr RB, Wagenknecht LE, Stern MP et al. Prediction of type 2 diabetes using simple measures of insulin resistance. Combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 2003; 52: 463-469.
22. Rutter MK, Meigs JB, Sullivan LM, D'Agostino Sr RB, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54: 3252-3257.
23. Morales PA, Mitchell BD, Valdez RA, Hazuda HP, Stern MP, Haffner SM. Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio Heart Study. Diabetes 1993; 42: 154-161.
24. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH. A two-step model for development of non-insulin-dependent diabetes. Am J Med 1991; 90: 229-235.